Read More

Care quality commission

He says his mum is " a little bit embarrassed" but very touched by all the support and still continues to go to work three days a week.

Lu177 cancer treatment at Addenbrooke's

Addenbrooke's says it is unable to comment on drug licensing issues.

Lu177 treatment is used to halt the growth of gastro pancreatic neuroendocrine tumours, but it is not licensed for re-treatment in Addenbrooke's patients who have previously received four cycles of treatment.

However it is still licensed for some patients who have tests that show their tumours are deemed to be receptive to the drug.